-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
DDX3-IN-2
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1919828-81-1.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 1919828-81-1 |
| Description | DDX3-IN-2 is an active DEADbox polypeptide 3 (DDX3) inhibitor (IC50 = 0.3 μM) with broad spectrum antiviral activity and the potential to overcome HIV resistance. |
Product Information
| Synonyms | Urea, N-[4-(4-butyl-1H-1,2,3-triazol-1-yl)phenyl]-N'-(2-methylphenyl)-; 1-[4-(4-butyltriazol-1-yl)phenyl]-3-(o-tolyl)urea |
| IUPAC Name | 1-[4-(4-butyltriazol-1-yl)phenyl]-3-(2-methylphenyl)urea |
| Molecular Weight | 349.43 |
| Molecular Formula | C20H23N5O |
| Canonical SMILES | CCCCC1=CN(N=N1)C2=CC=C(C=C2)NC(=O)NC3=CC=CC=C3C |
| InChI | InChI=1S/C20H23N5O/c1-3-4-8-17-14-25(24-23-17)18-12-10-16(11-13-18)21-20(26)22-19-9-6-5-7-15(19)2/h5-7,9-14H,3-4,8H2,1-2H3,(H2,21,22,26) |
| InChIKey | LZPQWTRWEKFHPZ-UHFFFAOYSA-N |
| Purity | ≥98% (HPLC) |
| Solubility | In Vitro: DMSO : 100 mg/mL(286.18 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.5 mg/mL (7.15 mM); Clear solution |
| Appearance | Off-white to gray (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 438 |
| Exact Mass | 349.19026037 |
| In Vitro | DDX3-IN-2 behaves as a competitive inhibitor with respect to the RNA substrate, which can be seen by the decrease in its inhibition potency as a function of increasing RNA substrate concentrations. DDX3-IN-2 is found to be completely inactive against the ATPase of DDX3, DDX1 helicase, and DENV NS3 helicase. |
| In Vivo | DDX3-IN-2 (20 mg/kg; tail vein injection) possesses excellent biocompatibility, and Wistar rats shows a good tolerance to the dose of 20 mg/kg. DDX3-IN-2 (10 mg/kg; i.v. bolus injection; 0~25 hours) rapidly eliminates the half-life elimination and the plasmatic clearance values. Result: Rapidly eliminated the half-life elimination and the plasmatic clearance values. |
| Target | HIV |
| XLogP3-AA | 4 |
